Roth Capital analyst Debjit Chattopadhyay came out with a research note on Vical Incorporated (NASDAQ:VICL), as the company is expected to release top-line data from its Phase 1/2 trial of HSV-2 vaccine by the middle of this year. Vical shares are currently trading at $1.00, up $0.02 or 2.04 percent.

Chattopadhyay wrote, “The ideal first generation HSV-2 vaccine should not only reduce/prevent symptomatic recurrences but also control asymptomatic viral shedding, providing a public health benefit by decreasing virus transmission to uninfected persons. While competitor Genocea (EV~$191M) is currently in pole position, the upcoming data from Vical (EV~$51M) if positive, could allow it to leapfrog ahead, in our view. Additionally, Vical’s partnered CMV asset should start attracting attention as we head into 2016.”

The analyst reiterated a Buy rating on Vical shares with a price target of $4.65, which represents a potential upside of 374% from where the stock is currently trading.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 34.2% and a 73.2% success rate. Chattopadhyay ranked #12 out of 3612 analysts.